Papadakis, Emmanouil <br/><br/>
A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.  [electronic resource] 

 -  Oncotarget  Apr 2016 
 - 18851-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7944  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aniline Compounds--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Benzothiazoles--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Cell Proliferation--drug effects<br/>Combined Modality Therapy<br/>DNA-Binding Proteins--antagonists & inhibitors<br/>Drug Synergism<br/>Female<br/>Humans<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>RNA, Small Interfering--administration & dosage<br/>Receptor, ErbB-2--biosynthesis<br/>Transcription Factors--antagonists & inhibitors<br/>Transfection<br/>Trastuzumab--administration & dosage<br/>Xenograft Model Antitumor Assays